

Gherardo Mazziotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/219287/publications.pdf>

Version: 2024-02-01

268
papers

12,545
citations

25034

57
h-index

32842

100
g-index

285
all docs

285
docs citations

285
times ranked

10225
citing authors

#	ARTICLE	IF	CITATIONS
1	Lack of <i>GNAS</i> Remethylation During Oogenesis May Be a Cause of Sporadic Pseudohypoparathyroidism Type Ib. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1610-e1619.	3.6	5
2	Low testosterone predicts hypoxemic respiratory insufficiency and mortality in patients with COVID-19 disease: another piece in the COVID puzzle. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 753-762.	3.3	16
3	Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors. <i>European Journal of Endocrinology</i> , 2022, 186, P1-P33.	3.7	26
4	Direct effects of octreotide on osteoblast cell proliferation and function. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1045-1057.	3.3	7
5	Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19 hospitalized patients. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13753.	3.4	13
6	Skeletal disorders associated with the growth hormone-insulin-like growth factor 1 axis. <i>Nature Reviews Endocrinology</i> , 2022, 18, 353-365.	9.6	39
7	Pseudohypoparathyroidism. <i>VideoEndocrinology</i> , 2022, 9, 2-3.	0.1	0
8	Case Report: A Novel <i>ARMC5</i> Germline Mutation in a Patient with Primary Bilateral Macronodular Adrenal Hyperplasia and Hypogammaglobulinemia. <i>Frontiers in Genetics</i> , 2022, 13, 834067.	2.3	2
9	Somatostatin receptors regulation in corticotroph tumors: the role of cytoskeleton and <i>USP8</i> mutations. <i>Endocrine Oncology</i> , 2022, , .	0.4	0
10	Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: Reliability of WHO fracture risk assessment tool (FRAX) and bone mineral density in real-life clinical practice. <i>Journal of Bone Oncology</i> , 2022, 33, 100421.	2.4	10
11	Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges. <i>World Journal of Gastroenterology</i> , 2022, 28, 1430-1443.	3.3	5
12	Expected and paradoxical effects of obesity on cancer treatment response. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 681-702.	5.7	17
13	Vertebral Fractures Associated with Spinal Sagittal Imbalance and Quality of Life in Acromegaly: A Radiographic Study with EOS 2D/3D Technology. <i>Neuroendocrinology</i> , 2021, 111, 775-785.	2.5	17
14	Skeletal health in patients with differentiated thyroid carcinoma. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 431-442.	3.3	15
15	Impact of age on postsurgical outcomes of nonfunctioning pituitary adenomas. <i>Endocrine</i> , 2021, 72, 915-922.	2.3	12
16	Pseudohypoparathyroidism, acrodysostosis, progressive osseous heteroplasia: different names for the same spectrum of diseases?. <i>Endocrine</i> , 2021, 72, 611-618.	2.3	7
17	The benefit of statins in SARS-CoV-2 patients: further metabolic and prospective clinical studies are needed. <i>Endocrine</i> , 2021, 71, 270-272.	2.3	19
18	Adrenal Insufficiency at the Time of COVID-19: A Retrospective Study in Patients Referring to a Tertiary Center. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1354-e1361.	3.6	28

#	ARTICLE	IF	CITATIONS
19	Managing Menopausal Symptoms in Young Women With Breast Cancer: When Medicine Is Not All. The Take Care Project. <i>Clinical Breast Cancer</i> , 2021, 21, e547-e560.	2.4	3
20	Inactivating PTH/PTHrP signaling disorders (iPPSDs): evaluation of the new classification in a multicenter large series of 544 molecularly characterized patients. <i>European Journal of Endocrinology</i> , 2021, 184, 311-320.	3.7	13
21	Update on vertebral fractures in pituitary diseases: from research to clinical practice. <i>Hormones</i> , 2021, 20, 423-437.	1.9	6
22	Pseudohypoparathyroidism: Focus on Cerebral and Renal Calcifications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3005-e3020.	3.6	6
23	Vitamin D deficiency, secondary hyperparathyroidism and respiratory insufficiency in hospitalized patients with COVID-19. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2285-2293.	3.3	18
24	Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells. <i>Molecular and Cellular Endocrinology</i> , 2021, 524, 111159.	3.2	5
25	Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study. <i>Endocrine</i> , 2021, 73, 255-260.	2.3	16
26	The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors. <i>Molecular and Cellular Endocrinology</i> , 2021, 527, 111226.	3.2	3
27	Drug resistance in pituitary tumours: from cell membrane to intracellular signalling. <i>Nature Reviews Endocrinology</i> , 2021, 17, 560-571.	9.6	8
28	Case Report: A Challenging Localization of a Pulmonary Ectopic ACTH-Secreting Tumor in a Patient With Severe Cushing's Syndrome. <i>Frontiers in Endocrinology</i> , 2021, 12, 687539.	3.5	5
29	Mineral and Bone Consequences of High Dose Denosumab Therapy to Treat an Aneurysmal Bone Cyst, a Child Case Report. <i>Frontiers in Endocrinology</i> , 2021, 12, 698963.	3.5	6
30	PTH resistance. <i>Molecular and Cellular Endocrinology</i> , 2021, 531, 111311.	3.2	2
31	The "Parachute" Technique for the Endoscopic Repair of High-Flow Anterior Skull-Base CSF Leaks. <i>World Neurosurgery</i> , 2021, 151, e880-e887.	1.3	4
32	Clinical and hormonal findings in patients presenting with high IGF-1 and growth hormone suppression after oral glucose load: a retrospective cohort study. <i>European Journal of Endocrinology</i> , 2021, 185, 289-297.	3.7	5
33	Hyperandrogenism by Liquid Chromatography Tandem Mass Spectrometry in PCOS: Focus on Testosterone and Androstenedione. <i>Journal of Clinical Medicine</i> , 2021, 10, 119.	2.4	10
34	Hypoparathyroidism and pseudohypoparathyroidism in pregnancy: an Italian retrospective observational study. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 421.	2.7	5
35	Procoagulant Imbalance in Klinefelter Syndrome Assessed by Thrombin Generation Assay and Whole-Blood Thromboelastometry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1660-e1672.	3.6	7
36	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e937-e946.	3.6	207

#	ARTICLE	IF	CITATIONS
37	High bone marrow fat in patients with Cushing's syndrome and vertebral fractures. <i>Endocrine</i> , 2020, 67, 172-179.	2.3	20
38	Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy. <i>Diabetes Care</i> , 2020, 43, 3042-3049.	8.6	112
39	Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders: An Updated Practical Tool for Physicians and Patients. <i>Hormone Research in Paediatrics</i> , 2020, 93, 182-196.	1.8	42
40	SARS-CoV-2-related atypical thyroiditis. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 739-741.	11.4	225
41	Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment. <i>Cancers</i> , 2020, 12, 2143.	3.7	13
42	Abdominal Aortic Calcification as a Marker of Relationship Between Atherosclerosis and Skeletal Fragility. <i>Journal of Clinical Densitometry</i> , 2020, 23, 539-542.	1.2	9
43	Arterial Embolization and Second-Look in Spindle Cell Oncocytoma of the Pituitary Gland: Case Report and Review of Literature. <i>World Neurosurgery</i> , 2020, 142, 87-92.	1.3	2
44	Prevalence and determinants of radiological vertebral fractures in patients with Klinefelter syndrome. <i>Andrology</i> , 2020, 8, 1699-1704.	3.5	15
45	Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in) Tj ETQq1 1 0.784314 rgBT ₁₈ /Overl	3.6	18
46	Letter to the Editor from Mazziotti et al: "Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-Based Study". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3836-e3837.	3.6	5
47	Italian Association of Clinical Endocrinologists (AME) and Italian ACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 1: Diagnostic and Clinical Issues. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2020, 20, 1133-1143.	1.2	4
48	The suprasellar volume of nonfunctioning pituitary adenomas: a useful tool for predicting visual field deficits. <i>Pituitary</i> , 2020, 23, 552-557.	2.9	2
49	Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies. <i>Journal of Clinical Oncology</i> , 2020, 38, 3363-3366.	1.6	22
50	Clinically Nonfunctioning Pituitary Incidentalomas: Characteristics and Natural History. <i>Neuroendocrinology</i> , 2020, 110, 595-603.	2.5	24
51	A severe inactivating PTH/PTHrP signaling disorder type 2 in a patient carrying a novel large deletion of the GNAS gene: a case report and review of the literature. <i>Endocrine</i> , 2020, 67, 466-472.	2.3	2
52	Morphometric vertebral fractures in patients with castration-resistant prostate cancer undergoing treatment with radium-223: a longitudinal study in the real-life clinical practice. <i>Endocrine</i> , 2020, 69, 204-211.	2.3	5
53	Secondary hyperparathyroidism and thoracic vertebral fractures in heart failure middle-aged patients: a 3-year prospective study. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1561-1569.	3.3	8
54	Italian Association of Clinical Endocrinologists (AME) and Italian ACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 2: Therapeutic Issues. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2020, 20, 1144-1155.	1.2	4

#	ARTICLE	IF	CITATIONS
55	A novel insight into the anticancer mechanism of metformin in pancreatic neuroendocrine tumor cells. <i>Molecular and Cellular Endocrinology</i> , 2020, 509, 110803.	3.2	10
56	Case Report: Late-Onset Congenital Adrenal Hyperplasia and Acute Covid-19 Infection in a Pregnant Woman: Multidisciplinary Management. <i>Frontiers in Endocrinology</i> , 2020, 11, 602535.	3.5	0
57	Thyrotoxicosis in patients with COVID-19: the THYRCOV study. <i>European Journal of Endocrinology</i> , 2020, 183, 381-387.	3.7	262
58	Growth hormone therapy at the time of Covid-19 pandemic: adherence and drug supply issues. <i>European Journal of Endocrinology</i> , 2020, 183, L13-L15.	3.7	13
59	TNM 8th edition in thyroid cancer staging: is there an improvement in predicting recurrence?. <i>Endocrine-Related Cancer</i> , 2020, 27, 325-336.	3.1	12
60	Suboptimal medication adherence may favor the progression of vertebral fractures in women with post-menopausal osteoporosis treated with denosumab. <i>Minerva Endocrinologica</i> , 2020, 45, 165-171.	1.8	8
61	Novel Pathogenetic Variants in PTHLH and TRPS1 Genes Causing Syndromic Brachydactyly. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 465-474.	2.8	4
62	The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell-mediated resistance to metastasis. <i>Nature Immunology</i> , 2019, 20, 1012-1022.	14.5	75
63	Medullary thyroid carcinoma treated with percutaneous ultrasound-guided radiofrequency ablation. <i>Endocrine</i> , 2019, 65, 515-519.	2.3	9
64	Hypercalcaemia in pseudohypoparathyroidism type 1A and type 1B. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2019, 2019, .	0.5	4
65	Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas. <i>Hormones and Cancer</i> , 2019, 10, 120-127.	4.9	11
66	FGF23 and Fetuin-A Interaction and Mesenchymal Osteogenic Transformation. <i>International Journal of Molecular Sciences</i> , 2019, 20, 915.	4.1	2
67	Unrecognized Pseudohypoparathyroidism Type 1A as a Cause of Hypocalcemia and Seizures in a 64-Year-Old Woman. <i>Case Reports in Endocrinology</i> , 2019, 2019, 1-5.	0.4	3
68	Recovery of Adrenal Function after Pituitary Surgery in Patients with Cushing Disease: Persistent Remission or Recurrence?. <i>Neuroendocrinology</i> , 2019, 108, 211-218.	2.5	10
69	Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study. <i>European Journal of Endocrinology</i> , 2019, 180, 311-320.	3.7	16
70	MANAGEMENT OF ENDOCRINE DISEASE: Bone disorders associated with acromegaly: mechanisms and treatment. <i>European Journal of Endocrinology</i> , 2019, 181, R45-R56.	3.7	42
71	High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone Suppressive Therapy for Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 956-964.	3.6	39
72	HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy. <i>Calcified Tissue International</i> , 2018, 103, 151-163.	3.1	23

#	ARTICLE	IF	CITATIONS
73	Genetic and Epigenetic Defects at the GNAS Locus Lead to Distinct Patterns of Skeletal Growth but Similar Early-Onset Obesity. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1480-1488.	2.8	41
74	Multiple hormone resistance and alterations of G-protein-coupled receptors signaling. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2018, 32, 141-154.	4.7	13
75	Neuroendocrinology of Bone Metabolism. <i>Endocrinology</i> , 2018, , 513-526.	0.1	0
76	Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. <i>Pituitary</i> , 2018, 21, 302-308.	2.9	30
77	Rathke's cleft cyst associated with pituitary granulomatosis with polyangiitis: An unusual combination of hypothalamus-pituitary region pathologies. <i>Radiology Case Reports</i> , 2018, 13, 233-236.	0.6	0
78	Bone safety of dual-release hydrocortisone in patients with hypopituitarism. <i>Endocrine</i> , 2018, 60, 528-531.	2.3	29
79	Acromegalic osteopathy: An update. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2018, 3, 1-6.	1.4	2
80	Subclinical thyrotoxicosis and bone. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2018, 3, 25-30.	1.4	1
81	Vitamin D and Glucocorticoid-Induced Osteoporosis. <i>Frontiers of Hormone Research</i> , 2018, , 149-160.	1.0	7
82	Prevalence of morphometric vertebral fractures in "difficult" patients with acromegaly with different biochemical outcomes after multimodal treatment. <i>Endocrine</i> , 2018, 59, 449-453.	2.3	29
83	A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment. <i>International Journal of Cancer</i> , 2018, 142, 1842-1852.	5.1	22
84	Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience. <i>Endocrine</i> , 2018, 59, 90-101.	2.3	35
85	Parathyroid hormone resistance syndromes " Inactivating PTH/PTHrP signaling disorders (iPPSDs). <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2018, 32, 941-954.	4.7	15
86	High Prevalence of Radiological Vertebral Fractures in Patients With TSH-Secreting Pituitary Adenoma. <i>Journal of the Endocrine Society</i> , 2018, 2, 1089-1099.	0.2	16
87	GH/IGF-I and Bone. , 2018, , 83-106.		0
88	Pituitary Diseases and Bone. <i>Endocrine Reviews</i> , 2018, 39, 440-488.	20.1	107
89	Natural history of Rathke's cleft cysts: A retrospective analysis of a two centres experience. <i>Clinical Endocrinology</i> , 2018, 89, 178-186.	2.4	27
90	Primary hyperparathyroidism in prostate cancer: guilty or not guilty?. <i>Endocrine</i> , 2018, 62, 271-273.	2.3	0

#	ARTICLE	IF	CITATIONS
91	Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-12.	1.5	49
92	Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. <i>Nature Reviews Endocrinology</i> , 2018, 14, 476-500.	9.6	224
93	Single-Molecule Microscopy Reveals Dynamic FLNA Interactions Governing SSTR2 Clustering and Internalization. <i>Endocrinology</i> , 2018, 159, 2953-2965.	2.8	22
94	Prolactin: Regulation of Secretion and Action. , 2018, , 157-164.		2
95	MANAGEMENT OF ENDOCRINE DISEASE: Therapeutics of vitamin D. <i>European Journal of Endocrinology</i> , 2018, 179, R239-R259.	3.7	53
96	Possible delayed diagnosis and treatment of metastatic differentiated thyroid cancer by adopting the 2015 ATA guidelines. <i>European Journal of Endocrinology</i> , 2018, 179, 143-151.	3.7	39
97	Neuroendocrinology of Bone Metabolism. <i>Endocrinology</i> , 2018, , 1-15.	0.1	0
98	The impact of body composition on vertebral fractures during aromatase inhibitors therapy: A cross-sectional study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e12504-e12504.	1.6	0
99	Is Complex Sphenoidal Sinus Anatomy a Contraindication to a Transsphenoidal Approach for Resection of Sellar Lesions? Case Series and Review of the Literature. <i>World Neurosurgery</i> , 2017, 100, 173-179.	1.3	20
100	Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study. <i>Bone</i> , 2017, 97, 147-152.	2.9	33
101	Focus on GH deficiency and thyroid function. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 71-78.	4.7	15
102	Pegvisomant in acromegaly: an update. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 577-589.	3.3	53
103	Fibrocartilaginous mesenchymoma of bone: a single institution experience with molecular investigations and a review of the literature. <i>Histopathology</i> , 2017, 71, 134-142.	2.9	11
104	Hypothyroidism associated with parathyroid disorders. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 161-173.	4.7	8
105	High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2454-2464.	3.6	51
106	Long-Standing Isolated Autoimmune Hypophysitis Diagnosed with Endoscopic Transventricular Biopsy. <i>World Neurosurgery</i> , 2017, 105, 1036.e5-1036.e9.	1.3	9
107	Diabetes in Cushing Disease. <i>Current Diabetes Reports</i> , 2017, 17, 32.	4.2	31
108	Growth hormone deficiency in treated acromegaly and active Cushing's syndrome. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 79-90.	4.7	14

#	ARTICLE	IF	CITATIONS
109	Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects. Expert Opinion on Pharmacotherapy, 2017, 18, 1679-1689.	1.8	21
110	Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. Pituitary, 2017, 20, 489-498.	2.9	233
111	Acromegalic osteopathy. Pituitary, 2017, 20, 63-69.	2.9	38
112	Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line. Endocrine, 2017, 56, 146-157.	2.3	12
113	MANAGEMENT OF ENDOCRINE DISEASE: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects. European Journal of Endocrinology, 2017, 177, R231-R248.	3.7	58
114	FLNA is implicated in pulmonary neuroendocrine tumors aggressiveness and progression. Oncotarget, 2017, 8, 77330-77340.	1.8	34
115	The Importance of Networking in Pseudohypoparathyroidism: EuroPHP Network and Patient Support Associations. Pediatric Endocrinology Reviews, 2017, 15, 92-97.	1.2	2
116	Screening of <i>PRKAR1A</i> and <i>PDE4D</i> in a Large Italian Series of Patients Clinically Diagnosed With Albright Hereditary Osteodystrophy and/or Pseudohypoparathyroidism. Journal of Bone and Mineral Research, 2016, 31, 1215-1224.	2.8	47
117	Current and future medical treatments for patients with acromegaly. Expert Opinion on Pharmacotherapy, 2016, 17, 1631-1642.	1.8	27
118	Current and Emerging Aspects of Diabetes Mellitus in Acromegaly. Trends in Endocrinology and Metabolism, 2016, 27, 470-483.	7.1	102
119	Skeletal Fragility in Endogenous Hypercortisolism. Frontiers of Hormone Research, 2016, 46, 66-73.	1.0	21
120	Genome-wide DNA methylation analysis of pseudohypoparathyroidism patients with GNAS imprinting defects. Clinical Epigenetics, 2016, 8, 10.	4.1	53
121	The Modern Criteria for Medical Management of Acromegaly. Progress in Molecular Biology and Translational Science, 2016, 138, 63-83.	1.7	33
122	Pseudohypoparathyroidism and Gs α -cAMP-linked disorders: current view and open issues. Nature Reviews Endocrinology, 2016, 12, 347-356.	9.6	91
123	High-resolution-cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures. Endocrine, 2016, 54, 532-542.	2.3	52
124	The Prevalence of GNAS Deficiency-Related Diseases in a Large Cohort of Patients Characterized by the EuroPHP Network. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3657-3668.	3.6	66
125	New medical therapies of acromegaly. Growth Hormone and IGF Research, 2016, 30-31, 58-63.	1.1	15
126	Vitamin D-binding protein: one more piece in the puzzle of acromegalic osteopathy?. Endocrine, 2016, 52, 183-186.	2.3	16

#	ARTICLE	IF	CITATIONS
127	Expression of protein kinase A regulatory subunits in benign and malignant human thyroid tissues: A systematic review. <i>Experimental Cell Research</i> , 2016, 346, 85-90.	2.6	7
128	Bone and Joint Disorders in Acromegaly. <i>Neuroendocrinology</i> , 2016, 103, 86-95.	2.5	60
129	High prevalence of radiological vertebral fractures in adult patients with Ehlers-Danlos syndrome. <i>Bone</i> , 2016, 84, 88-92.	2.9	41
130	Treatment of hypothyroidism: all that glitters is gold?. <i>Endocrine</i> , 2016, 52, 411-413.	2.3	14
131	Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects. <i>Endocrine-Related Cancer</i> , 2016, 23, 221-233.	3.1	75
132	Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. <i>Endocrine</i> , 2016, 52, 103-110.	2.3	56
133	Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. <i>Journal of Neuro-Oncology</i> , 2016, 126, 519-525.	2.9	105
134	Prompt clinical and biochemical response to denosumab in a young adult patient with craniofacial fibrous dysplasia. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2016, 13, 253-256.	1.0	21
135	Parathyroid hormone pulsatility: physiological and clinical aspects. <i>Bone Research</i> , 2015, 3, 14049.	11.4	40
136	Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton Involvement. <i>Frontiers in Endocrinology</i> , 2015, 6, 187.	3.5	28
137	Pituitary Diseases and Bone. <i>Endocrinology and Metabolism Clinics of North America</i> , 2015, 44, 171-180.	3.2	36
138	Screening for ACTH-dependent hypercortisolism in patients affected with pituitary incidentaloma. <i>European Journal of Endocrinology</i> , 2015, 172, 363-369.	3.7	19
139	Growth hormone deficiency in treated acromegaly. <i>Trends in Endocrinology and Metabolism</i> , 2015, 26, 11-21.	7.1	20
140	Bone Turnover, Bone Mineral Density, and Fracture Risk in Acromegaly: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 384-394.	3.6	139
141	Pseudohypoparathyroidism type Ib in 2015. <i>Annales D'Endocrinologie</i> , 2015, 76, 101-104.	1.4	9
142	Cortisol and the muscle-bone axis: response to comments by Molino et al.. <i>Osteoporosis International</i> , 2015, 26, 1661-1662.	3.1	3
143	Growth hormone replacement therapy and fracture risk. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 307-308.	11.4	10
144	cAMP effects in neuroendocrine tumors: The role of Epac and PKA in cell proliferation and adhesion. <i>Experimental Cell Research</i> , 2015, 339, 241-251.	2.6	17

#	ARTICLE	IF	CITATIONS
145	European guidance for the molecular diagnosis of pseudohypoparathyroidism not caused by point genetic variants at GNAS: an EQA study. <i>European Journal of Human Genetics</i> , 2015, 23, 438-444.	2.8	27
146	Insulin and GH/IGF-I axis: endocrine pacer or endocrine disruptor?. <i>Acta Diabetologica</i> , 2015, 52, 433-443.	2.5	21
147	Different expression of protein kinase A (PKA) regulatory subunits in normal and neoplastic thyroid tissues. <i>Histology and Histopathology</i> , 2015, 30, 473-8.	0.7	6
148	Diagnostic features and outcome of surgical therapy of acromegalic patients: Experience of the last three decades. <i>Hormones</i> , 2014, 13, 95-103.	1.9	15
149	Reevaluation of Acromegalic Patients in Long-Term Remission according to Newly Proposed Consensus Criteria for Control of Disease. <i>International Journal of Endocrinology</i> , 2014, 2014, 1-8.	1.5	8
150	GH receptor isoforms and skeletal fragility in acromegaly. <i>European Journal of Endocrinology</i> , 2014, 171, 237-245.	3.7	25
151	Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism. <i>European Journal of Endocrinology</i> , 2014, 170, 893-899.	3.7	34
152	Molecular imaging in acromegaly. <i>Nuclear Medicine Communications</i> , 2014, 35, 897-899.	1.1	1
153	Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?. <i>Osteoporosis International</i> , 2014, 25, 441-446.	3.1	49
154	Brachydactyly and atrial septal defect: When the digits point to the heart. <i>International Journal of Cardiology</i> , 2014, 177, e90-e92.	1.7	1
155	Growth Hormone, Insulin-Like Growth Factor-1, and the Kidney: Pathophysiological and Clinical Implications. <i>Endocrine Reviews</i> , 2014, 35, 234-281.	20.1	171
156	Thyrotropin-Secreting Pituitary Adenomas: Outcome of Pituitary Surgery and Irradiation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2069-2076.	3.6	79
157	Outcome of glucose homeostasis in patients with glucocorticoid-induced osteoporosis undergoing treatment with bone active-drugs. <i>Bone</i> , 2014, 67, 175-180.	2.9	20
158	Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1619-1635.	4.1	33
159	Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection. <i>Osteoporosis International</i> , 2014, 25, 2263-2269.	3.1	17
160	Elevated intraocular pressure in patients with acromegaly. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2014, 252, 1133-1139.	1.9	7
161	Impaired growth hormone secretion associated with low glucocorticoid levels: an experimental model for the Giustina effect. <i>Endocrine</i> , 2014, 47, 354-356.	2.3	12
162	Octreotide for acromegaly treatment: a reappraisal. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2433-2447.	1.8	32

#	ARTICLE	IF	CITATIONS
163	Glucocorticoids and the regulation of growth hormone secretion. <i>Nature Reviews Endocrinology</i> , 2013, 9, 265-276.	9.6	144
164	Effects of Recombinant Follicle-Stimulating Hormone on Bone Turnover Markers in Infertile Women Undergoing <i>in Vitro</i> Fertilization Procedure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 330-336.	3.6	14
165	Vertebral Fractures in Patients With Acromegaly: A 3-Year Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3402-3410.	3.6	131
166	Clinical utility gene card for: Pseudohypoparathyroidism. <i>European Journal of Human Genetics</i> , 2013, 21, 5-5.	2.8	20
167	Commentary. <i>Neurosurgery</i> , 2013, 73, E746-E748.	1.1	10
168	Prevalence of thoracic vertebral fractures in hospitalized elderly patients with heart failure. <i>European Journal of Endocrinology</i> , 2012, 167, 865-872.	3.7	24
169	Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly. <i>PLoS ONE</i> , 2012, 7, e36411.	2.5	167
170	Growth Hormone Receptor Variants and Response to Pegvisomant in Monotherapy or in Combination with Somatostatin Analogs in Acromegalic Patients: A Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E165-E172.	3.6	41
171	High prevalence of radiological vertebral fractures in HIV-infected males. <i>Endocrine</i> , 2012, 41, 512-517.	2.3	52
172	New understanding and treatments for osteoporosis. <i>Endocrine</i> , 2012, 41, 58-69.	2.3	131
173	Diabetes in Cushing syndrome: basic and clinical aspects. <i>Trends in Endocrinology and Metabolism</i> , 2011, 22, 499-506.	7.1	164
174	Pseudohypoparathyroidism: Diagnosis and Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3020-3030.	3.6	250
175	High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. <i>Pituitary</i> , 2011, 14, 299-306.	2.9	70
176	Vertebral fractures in males with prolactinoma. <i>Endocrine</i> , 2011, 39, 288-293.	2.3	85
177	Influence of diabetes mellitus on vertebral fractures in men with acromegaly. <i>Endocrine</i> , 2011, 40, 102-108.	2.3	53
178	Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. <i>European Journal of Endocrinology</i> , 2011, 164, 341-347.	3.7	44
179	Acromegaly secondary to an incidentally discovered growth-hormone-releasing hormone secreting bronchial carcinoid tumour associated to a pituitary incidentaloma. <i>Pituitary</i> , 2010, 13, 289-292.	2.9	6
180	Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. <i>Pituitary</i> , 2010, 13, 60-67.	2.9	84

#	ARTICLE	IF	CITATIONS
181	Glucocorticoid-induced Osteoporosis. , 2010, , 415-421.		0
182	Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. European Journal of Endocrinology, 2010, 163, 15-20.	3.7	58
183	Recombinant Human GH Replacement Therapy in Children with Pseudohypoparathyroidism Type Ia: First Study on the Effect on Growth. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 5011-5017.	3.6	55
184	Drug-induced Osteoporosis: Mechanisms and Clinical Implications. American Journal of Medicine, 2010, 123, 877-884.	1.5	234
185	Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density. Bone, 2010, 46, 747-751.	2.9	97
186	Osteoporosis in Human Immunodeficiency Virus Patients – An Emerging Clinical Concern. European Endocrinology, 2010, 10, 79.	1.5	3
187	Glucocorticoid-induced osteoporosis and parathyroid hormone. Journal of Endocrinological Investigation, 2010, 33, 16-21.	3.3	7
188	High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. European Journal of Endocrinology, 2009, 161, 331-338.	3.7	109
189	Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1500-1508.	3.6	191
190	Treatment of glucocorticoid-induced osteoporosis. Therapeutic Advances in Musculoskeletal Disease, 2009, 1, 27-34.	2.7	11
191	Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly. Pituitary, 2009, 12, 196-199.	2.9	46
192	TREATMENT WITH METFORMIN IS PROTECTIVE AGAINST LIMITATIONS IN INSTRUMENTAL ACTIVITIES OF DAILY LIVING IN OLDER SUBJECTS WITH TYPE 2 DIABETES MELLITUS. Journal of the American Geriatrics Society, 2009, 57, 562-564.	2.6	7
193	Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone, 2009, 45, 784-788.	2.9	73
194	Hypovitaminosis D and prevalence of vertebral fractures in women with GIO. Bone, 2009, 45, S140-S141.	2.9	0
195	The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. Pituitary, 2008, 11, 13-20.	2.9	46
196	Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency. Pituitary, 2008, 11, 55-61.	2.9	40
197	Growth Hormone, Insulin-Like Growth Factors, and the Skeleton. Endocrine Reviews, 2008, 29, 535-559.	20.1	715
198	Biochemical Evaluation of Patients with Active Acromegaly and Type 2 Diabetes Mellitus: Efficacy and Safety of the Galanin Test. Neuroendocrinology, 2008, 88, 299-304.	2.5	12

#	ARTICLE	IF	CITATIONS
199	Relationship between instrumental activities of daily living and blood glucose control in elderly subjects with type 2 diabetes. <i>Age and Ageing</i> , 2008, 37, 222-225.	1.6	30
200	Prevalence of Vertebral Fractures in Men with Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4649-4655.	3.6	144
201	Prevention and treatment of glucocorticoid-induced osteoporosis. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 53-8.	3.3	6
202	Glucocorticoid-Induced osteoporosis: clinical and therapeutic aspects. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2007, 51, 1404-1412.	1.3	30
203	Glucocorticoid-induced osteoporosis: pathophysiology and therapy. <i>Osteoporosis International</i> , 2007, 18, 1319-1328.	3.1	914
204	Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. <i>Pituitary</i> , 2007, 10, 227-232.	2.9	42
205	Active acromegaly enhances spontaneous parathyroid hormone pulsatility. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 736-740.	3.4	13
206	Development of Graves' hyperthyroidism during the early phase of pregnancy in a patient with pre-existing and long-standing Hashimoto's hypothyroidism. <i>Journal of Endocrinological Investigation</i> , 2006, 29, 288-290.	3.3	8
207	Resistance to somatostatin analogs in acromegaly: An evolving concept?. <i>Journal of Endocrinological Investigation</i> , 2006, 29, 86-93.	3.3	66
208	Glucocorticoid-induced osteoporosis: an update. <i>Trends in Endocrinology and Metabolism</i> , 2006, 17, 144-149.	7.1	311
209	Imbalance of the Osteoprotegerin/RANKL Ratio in Bone Marrow Microenvironment After Allogeneic Hemopoietic Stem Cell Transplantation. <i>Transplantation</i> , 2006, 82, 1449-1456.	1.0	11
210	Increased Prevalence of Radiological Spinal Deformities in Adult Patients With GH Deficiency: Influence of GH Replacement Therapy. <i>Journal of Bone and Mineral Research</i> , 2006, 21, 520-528.	2.8	113
211	Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects. <i>Pituitary</i> , 2006, 9, 221-229.	2.9	51
212	Growth hormone deficiency in the adult. <i>Pituitary</i> , 2006, 9, 305-311.	2.9	57
213	HMG-CoA reductase inhibitors inhibit rat propylthiouracil-induced goiter by modulating the ras-MAPK pathway. <i>Journal of Molecular Medicine</i> , 2006, 84, 967-973.	3.9	19
214	Thyroid Autoimmunity and Spontaneous Cervical Artery Dissection. <i>Stroke</i> , 2006, 37, 2375-2377.	2.0	30
215	Comparison between Six-Year Therapy with Long-Acting Somatostatin Analogs and Successful Surgery in Acromegaly: Effects on Cardiovascular Risk Factors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 121-128.	3.6	88
216	Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism. <i>European Journal of Endocrinology</i> , 2006, 154, 373-377.	3.7	18

#	ARTICLE	IF	CITATIONS
217	Serum Thyrotropin Receptor Antibodies Concentrations in Patients with Graves' Disease Before, at the End of Methimazole Treatment, and After Drug Withdrawal: Evidence That the Activity of Thyrotropin Receptor Antibody and/or Thyroid Response Modify During the Observation Period. <i>Thyroid</i> , 2006, 16, 295-302.	4.5	102
218	Increased Prevalence of Radiological Spinal Deformities in Active Acromegaly: A Cross-Sectional Study in Postmenopausal Women. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 1837-1844.	2.8	158
219	Innate and Acquired Immune System in Patients Developing Interferon- γ -Related Autoimmune Thyroiditis: A Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4138-4144.	3.6	33
220	Increased Cerebrospinal Fluid Levels of 3,5-Diiodo-L-thyronine in Patients with Alzheimer's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 198-202.	3.6	60
221	Biological activity of activating thyrotrophin receptor mutants: modulation by iodide. <i>Journal of Molecular Endocrinology</i> , 2005, 34, 209-220.	2.5	12
222	Reevaluating Thyrotropin Receptor-Induced Mouse Models of Graves' Disease and Ophthalmopathy. <i>Endocrinology</i> , 2005, 146, 835-844.	2.8	57
223	Cardiovascular risk in aging and obesity: Is there a role for GH?. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 759-767.	3.3	10
224	GH deficiency in the adult and bone. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 18-23.	3.3	10
225	Diagnosis and treatment of acromegaly and its complications: consensus guidelines. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 43-7.	3.3	4
226	Effect of Recombinant Human Growth Hormone (GH) Replacement on the Hypothalamic-Pituitary-Adrenal Axis in Adult GH-Deficient Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5397-5401.	3.6	91
227	Effects of increased thyroxine dosage pre-conception on thyroid function during early pregnancy. <i>European Journal of Endocrinology</i> , 2004, 151, 695-700.	3.7	53
228	Interferon- γ -Related Thyroid Disease: Pathophysiological, Epidemiological, and Clinical Aspects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3656-3661.	3.6	125
229	Recombinant Human TSH Modulates In Vivo C-Telopeptides of Type-1 Collagen and Bone Alkaline Phosphatase, but Not Osteoprotegerin Production in Postmenopausal Women Monitored for Differentiated Thyroid Carcinoma. <i>Journal of Bone and Mineral Research</i> , 2004, 20, 480-486.	2.8	113
230	Cushing's Syndrome and Bone. <i>Pituitary</i> , 2004, 7, 249-252.	2.9	122
231	High leptin levels in women developing postpartum thyroiditis. <i>Clinical Endocrinology</i> , 2004, 60, 208-213.	2.4	23
232	High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. <i>Bone</i> , 2004, 35, 785-791.	2.9	49
233	Autoimmune Thyroid Disease. , 2004, , 461-490.		0
234	Increased serum reverse triiodothyronine levels at diagnosis of hepatocellular carcinoma in patients with compensated HCV-related liver cirrhosis. <i>Clinical Endocrinology</i> , 2003, 58, 207-212.	2.4	24

#	ARTICLE	IF	CITATIONS
235	Grey-scale analysis allows a quantitative evaluation of thyroid echogenicity in the patients with Hashimoto's thyroiditis. <i>Clinical Endocrinology</i> , 2003, 59, 223-229.	2.4	60
236	Is chronic autoimmune thyroiditis a systemic disease?. <i>American Journal of Medicine</i> , 2003, 115, 412-413.	1.5	5
237	Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. <i>Obstetrics and Gynecology</i> , 2003, 101, 1177-1182.	2.4	102
238	Type-1 response in peripheral CD4+ and CD8+ T cells from patients with Hashimoto's thyroiditis. <i>European Journal of Endocrinology</i> , 2003, 148, 383-388.	3.7	64
239	Evolution of thyroid autoimmunity during iodine prophylaxis--the Sri Lankan experience. <i>European Journal of Endocrinology</i> , 2003, 149, 103-110.	3.7	48
240	Autoimmune Thyroiditis After Elimination of Iodine Deficiency in Sri Lanka. <i>Thyroid</i> , 2003, 13, 1187-1187.	4.5	6
241	Recombinant Human Thyrotropin Reduces Serum Vascular Endothelial Growth Factor Levels in Patients Monitored for Thyroid Carcinoma Even in the Absence of Thyroid Tissue. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4818-4822.	3.6	24
242	The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. <i>European Journal of Endocrinology</i> , 2002, 146, 743-749.	3.7	75
243	The influence of parity on multinodular goiter prevalence in areas with moderate iodine deficiency. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 442-446.	3.3	15
244	Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: A prospective study. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 624-630.	3.3	47
245	Eight parathyroid glands incidentally discovered during a surgical intervention for secondary hyperparathyroidism: An unusual clinical finding. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 800-803.	3.3	1
246	Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. <i>Cancer</i> , 2002, 95, 2539-2545.	4.1	97
247	Long-term effects of lanreotide SR and octreotide LAR [®] on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. <i>Clinical Endocrinology</i> , 2002, 56, 65-71.	2.4	115
248	Is the IFN-alpha-related thyroid autoimmunity an immunologically heterogeneous disease?. <i>Journal of Internal Medicine</i> , 2002, 252, 377-378.	6.0	9
249	Iodized salt improves the effectiveness of l-thyroxine therapy after surgery for nontoxic goitre: a prospective and randomized study. <i>Clinical Endocrinology</i> , 2002, 57, 507-513.	2.4	16
250	Interferon-related thyroid autoimmunity and long-term clinical outcome of chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2001, 33, 247-253.	0.9	33
251	Medullary thyroid cancer, papillary thyroid microcarcinoma and Graves' disease: An unusual clinical coexistence. <i>Journal of Endocrinological Investigation</i> , 2001, 24, 892-896.	3.3	19
252	Mutation of Somatostatin Receptor Type 5 in an Acromegalic Patient Resistant to Somatostatin Analog Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3809-3814.	3.6	99

#	ARTICLE	IF	CITATIONS
253	Long-Term Outcome of Interferon- β -Induced Thyroid Autoimmunity and Prognostic Influence of Thyroid Autoantibody Pattern at the End of Treatment. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1925-1929.	3.6	90
254	Long-Term Outcome of Interferon- β -Induced Thyroid Autoimmunity and Prognostic Influence of Thyroid Autoantibody Pattern at the End of Treatment. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1925-1929.	3.6	72
255	Parity as a Thyroid Size-Determining Factor in Areas with Moderate Iodine Deficiency. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4534-4537.	3.6	53
256	Recombinant Growth Hormone (GH) Therapy in GH-Deficient Adults: A Long-Term Controlled Study on Daily Versus Thrice Weekly Injections. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3720-3725.	3.6	57
257	Postintervention Serum TSH Levels May Be Useful to Differentiate Patients Who Should Undergo Levothyroxine Suppressive Therapy After Thyroid Surgery for Multinodular Goiter in a Region with Moderate Iodine Deficiency. Thyroid, 2000, 10, 1081-1085.	4.5	16
258	Long-term treatment with interferon- β therapy for multiple sclerosis and occurrence of Graves' disease. Journal of Endocrinological Investigation, 2000, 23, 321-324.	3.3	29
259	Recombinant Growth Hormone (GH) Therapy in GH-Deficient Adults: A Long-Term Controlled Study on Daily Versus Thrice Weekly Injections. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3720-3725.	3.6	17
260	Parity as a Thyroid Size-Determining Factor in Areas with Moderate Iodine Deficiency. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4534-4537.	3.6	14
261	Lack of association between changes in plasma leptin concentration and in food intake during the menstrual cycle. European Journal of Clinical Investigation, 1999, 29, 490-495.	3.4	26
262	Diabetes insipidus and increased serum levels of leptin and lactate-dehydrogenase (LDH) in an adolescent boy with a primary intracranial germinoma. Case Report and an endocrinological reevaluation of literature. Journal of Endocrinological Investigation, 1999, 22, 558-561.	3.3	2
263	Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon- β therapy for multiple sclerosis. Journal of Endocrinological Investigation, 1998, 21, 748-752.	3.3	63
264	An Improved Polymerase Chain Reaction (PCR) Protocol for Unambiguous Detection of Growth Hormone Gene Deletions. Journal of Pediatric Endocrinology and Metabolism, 1998, 11, 563-8.	0.9	5
265	Advancing age and insulin resistance: role of plasma tumor necrosis factor- β . American Journal of Physiology - Endocrinology and Metabolism, 1998, 275, E294-E299.	3.5	118
266	Insulin resistance and advancing age: What role for dehydroepiandrosterone sulfate?. Metabolism: Clinical and Experimental, 1997, 46, 1281-1286.	3.4	30
267	Spectral extinction measurements of spray combustion in a divided-chamber diesel engine system. Proceedings of the Combustion Institute, 1996, 26, 2533-2540.	0.3	11
268	Metformin and everolimus: A promising combination for neuroendocrine tumors treatment. Endocrine Abstracts, 0, , .	0.0	1